Parroting
In the Pipeline, what do fragments get you?
886 Million dollars, that's what! As pointed out by the buying company:
"Astex's unique fragment-based drug discovery technology [Ed: emphasis added] and clinical
oncology research and development capabilities, born out of the passion
of its researchers, exemplify our corporate mottos and belief in
"Sozosei (Creativity) and Jissho (Proof through Execution). I would like
Otsuka Pharmaceutical to continue to respect Astex's uniqueness and
leverage it to bring further growth for Otsuka Pharmaceutical."
Congratulations to the folks at Astex, the next time you see them at a conference, make sure they pick up the check.
No comments:
Post a Comment